Teiko Bio is looking for researchers studying immunotherapy response in melanoma or NSCLC

Do you have an idea for a translational research study in immunotherapy? 

If you are a physician or researcher with access to blood specimens of patients with advanced NSCLC or melanoma, we invite you to submit a proposal for a biomarker discovery study through immune profiling.

Why would you want to participate?

  • You will receive deep immune profiling mass cytometry [CyToF] data at no cost to you. 
    • Results are derived from supervised and unsupervised high-dimensional analysis on a 40-marker panel
    • Insights are provided by our team of PhD-trained immunologists and computational scientists.
    • Results are summarized in publication-quality reports. 
    • Normally offered at $4K per sample to drug companies, participating researchers would receive results at no-cost.
  • We will also provide support for preparing conference abstracts and writing manuscripts, if needed.

We will take care of all the logistics, sample-processing, secure data storage, and data analysis. In exchange, Teiko Bio is looking for inventorship on any resulting patent.

What do you need to be able to participate?

  • You should be able to share samples from patients with advanced (stage III / IV) NSCLC or melanoma who have been treated with immunotherapy. 
    • Samples can be cryopreserved peripheral blood mononuclear cells (PBMCs) or freshly-collected whole blood. 
    • Ideally, you would be able to provide 500K – 5M million cells / sample.
    • Samples should consist of at least one pre-treatment (baseline) and one on-treatment time point per patient.
  • We will need de-identified annotated clinical response data containing details on demographics, treatment, and clinical outcomes.

You can find a detailed list of required data here.

How do you apply?

You can submit your research proposal through the form on this web page. Applications will be considered on a rolling basis.

Upon receipt, we will evaluate your proposal on design, scientific feasibility and clinical relevance. Special consideration will be given to Stage IV melanoma patient cohorts treated with nivolumab in combination with relatlimab (Opdualag).

Teiko Bio is able to accommodate up to 3 proposals per indication; proposals will be evaluated on a rolling basis after each priority deadline.

If you have any questions, please reach out to info@teiko.bio.

We thank you for your interest and look forward to reviewing your proposal.